{{Rsnum
|rsid=8100018
|Gene=AKT2
|Chromosome=19
|position=40246116
|Orientation=plus
|GMAF=0.3108
|Gene_s=AKT2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 3.1 | 44.6 | 52.3
| HCB | 4.4 | 53.3 | 42.2
| JPT | 11.4 | 52.3 | 36.4
| YRI | 4.8 | 35.5 | 59.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 4.4 | 53.3 | 42.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=24421178
|Title=PI3K/PTEN/AKT/mTOR pathway genetic variations are associated with the clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment
}}{{PMID Auto
|PMID=18768676
|Title=First evidence of genetic association between AKT2 and polycystic ovary syndrome.
|OA=1
}}

{{PMID Auto
|PMID=19164214
|Title=Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
|OA=1
}}